Results 91 to 100 of about 16,960 (244)

Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups

Frontiers in Pharmacology
Introduction: Eplerenone is approved for the treatment of hypertension as well as symptomatic heart failure with reduced ejection fraction (HFrEF) following an acute myocardial infarction.
Xin Guan, Yusi Yang, Xinru Li, Yue Feng, Jizhen Li, Xuewen Li   +5 more
doaj   +1 more source

Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. [PDF]

PLoS ONE, 2013
Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness. Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and
Lene Boesby, Thomas Elung-Jensen, Svend Strandgaard, Anne-Lise Kamper   +3 more
doaj   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Rapid and MR-Independent IK1 activation by aldosterone during ischemia-reperfusion [PDF]

, 2015
In ST elevation myocardial infarction (STEMI) context, clinical studies have shown the deleterious effect of high aldosterone levels on ventricular arrhythmia occurrence and cardiac mortality.
Alexandre, J, Beygui, F, Guinamard, R, Hof, T, Manrique, A, Milliez, P., Puddu, Paolo Emilio, Rouet, R, Sallé, L   +8 more
core   +7 more sources

Effect of eplerenone on aldosterone and von Willebrand factor levelsin patients with myocardial infarction and chronic kidney disease

Zaporožskij Medicinskij Žurnal, 2022
Aim: to study the levels of aldosterone and von Willebrand factor (VWF) in patients with Q-wave acute myocardial infarction (Q-AMI) and underling chronic kidney disease (CKD) using aldosterone antagonists. Materials and methods.
V. K. Tashchuk, O. S. Polianska, O. I. Hulaha   +2 more
doaj   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Eplerenone inhibits aldosterone-induced CRP generation in rat vascular smooth muscle cells by regulating the MR-ROS-ERK1/2 signal pathway

European Journal of Inflammation, 2017
Atherosclerosis is a chronic inflammatory disease in the vessel wall. As a representative inflammatory cytokine, C-reactive protein (CRP) participates in the formation and development of atherosclerosis.
Xiaolu Zhang, Juntian Liu, Xiaoming Pang, Jingjing Zhao, Shouzhu Xu, Jing Zhao   +5 more
doaj   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Intramyocardial gene silencing by interfering RNA [PDF]

, 2017
RNAi is a widely used methodology for gene silencing. The action mechanism of siRNA molecules has been well studiedin recent years, and the technique has been optimized in terms of safety and effectiveness. Cardiovascular diseases havea high incidence in
Brea, María Soledad, Morgan, Patricio Eduardo, Perez, Nestor Gustavo   +2 more
core   +1 more source